An open-label, phase I, dose-escalation study to characterize the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous BAY1179470 in subjects with advanced, refractory solid tumors
Phase of Trial: Phase I
Latest Information Update: 18 Sep 2017
Price : $35 *
At a glance
- Drugs Aprutumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Bayer
- 24 Aug 2016 Status changed from active, no longer recruiting to completed.
- 03 Feb 2016 Planned End Date changed from 1 Mar 2016 to 1 Dec 2016, as reported by ClinicalTrials.gov record.
- 03 Feb 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Dec 2016, as reported by ClinicalTrials.gov record.